
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 7, 2013

SORRENTO THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation or organization)

000-52228
(Commission File Number)

33-0344842
IRS Employer
Identification No.)

6042 Cornerstone Ct. West, Suite B
San Diego, CA 92121
(Address of principal executive offices)

Registrant's telephone number, including area code: (858) 210-3700

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 8.01 Other Events.

On August 7, 2013, Sorrento Therapeutics, Inc. (the “Company”) and Lonza issued a press release announcing the signing of a non-exclusive research license agreement, for access to Lonza’s GS Xceed™ Gene Expression System. A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

| Exhibit No. | Description |
|--------------------|-------------------------------------|
| 99.1 | Press Release issued August 7, 2013 |

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 8, 2013

SORRENTO THERAPEUTICS, INC.

By: /s/ Richard Vincent
Name: Richard Vincent
Title: Chief Financial Officer and Secretary

Pharma&Biotech



6042 Cornerstone Court West
Suite B
San Diego, CA 92121, USA

Lonza

Lonza Group Ltd
Muenchensteinerstrasse 38
4002 Basel, Switzerland

Press Release

Sorrento Therapeutics, Inc. Licenses Lonza's GS Xceed™ Gene Expression System for the Research and Development of Human Therapeutic Antibodies

Basel, Switzerland and San Diego, CA (USA)—7 August 2013—Sorrento Therapeutics, Inc. (OTCQB: SRNE; SRNED; Sorrento) and Lonza announced today the signing of a non-exclusive research license agreement, for access to Lonza's GS Xceed™ Gene Expression System. The GS Xceed™ System will be used in the generation of stable expression cell lines for the production and development of therapeutic antibodies in Sorrento's product portfolio.

The research license agreement will give Sorrento access to Lonza's GS technology for use in Sorrento's maturing pipeline of therapeutic antibodies in oncology, inflammation, and infectious disease. Sorrento has shown yields of up to 3g/L with the GS Xceed™ System, in the production of antibodies targeting the vascular epidermal growth factor receptor 2 (VEGFR2), an important anti-angiogenesis target for a number of solid tumor indications. Several monoclonal antibodies (mAbs) will be produced and developed under the new agreement, including Sorrento's lead anti-PD-L1 and anti-PD-1 antibodies, as well as a selection of traditionally difficult-to-obtain anti-chemokine receptor mAbs.

"We are excited to license Lonza's GS Xceed™ System for the development of our lead human therapeutic antibody programs," commented Henry Ji, Ph.D., President and Chief Executive Officer of Sorrento Therapeutics. "The speed and ease of use of the GS Xceed™ System will aid in the rapid selection of high-producing cell lines and accelerate the production and development of our most promising therapeutic candidates."

"We look forward to supporting Sorrento's efforts to expand and develop its pipeline of promising new therapeutic candidates," said Karen Fallen, VP of Licensing and Technology, Lonza Development Services. "The GS Xceed System™ is an innovative and robust expression system derived from our industry-leading original GS System™ optimized through years of process development expertise."

Pharma&Biotech



Lonza

6042 Cornerstone Court West
Suite B
San Diego, CA 92121, USA

Lonza Group Ltd
Muenchensteinerstrasse 38
4002 Basel, Switzerland

Press Release

About Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc. is a publicly-traded, development-stage biopharmaceutical company engaged in the discovery, acquisition, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs in the United States, Europe and additional international markets. Sorrento Therapeutics' primary therapeutic focus is oncology but it is also developing therapeutics products for other indications, including inflammation, metabolic, and infectious diseases. Sorrento Therapeutics' proprietary G-MAB® fully-human antibody library platform was designed to facilitate the rapid identification and isolation of highly specific antibody therapeutic product candidates that bind to disease targets appropriate for antibody therapy. More information is available at www.sorrentotherapeutics.com

About the GS Xceed™ Gene Expression System™

The GS Xceed™ Gene Expression System and GS Gene Expression System™, are owned and licensed by Lonza, and used for the production of therapeutic recombinant proteins and monoclonal antibodies. Over 100 biotechnology and pharmaceutical companies and over 85 academic laboratories worldwide are successfully using the GS Gene Expression System™ which has established itself as the industry standard. The GS Xceed System™ is the second generation system to Lonza's established expression platform. Lonza's expression systems are characterized by their speed and ease of use; the higher yielding cell lines provide cost-efficient production of therapeutic proteins. Lonza's long and proven track record has made it a leader in the industry.

About Lonza

Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers' needs from research to final product manufacture. It is the global leader in the production and support of chemical and biological active pharmaceutical ingredients. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is also the world leader in microbial control providing innovative, chemistry-based and related solutions to destroy or to

Pharma&Biotech



Lonza

6042 Cornerstone Court West
Suite B
San Diego, CA 92121, USA

Lonza Group Ltd
Muenchensteinerstrasse 38
4002 Basel, Switzerland

Press Release

selectively inhibit the growth of harmful microorganisms. Its activities encompass the areas of water treatment, personal care, health and hygiene, industrial preservation, materials protection, and wood treatment. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition and agro markets.

Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange and secondary listed on the Singapore Exchange Securities Trading Limited ("SGX-ST"). In 2012, the company had sales of CHF 3.925 billion. Further information can be found at www.lonza.com.

Forward-Looking Statements

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Words such as "assumes," "plans," "believes," "expects," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements. Forward-looking statements include statements about the clinical trial results from third parties, and the preclinical and clinical development of Sorrento's human antibody therapeutics. All such forward-looking statements are based on Sorrento's current beliefs and expectations, and should not be regarded as a representation by Sorrento that any of its plans will be achieved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in Sorrento's businesses; the scope and validity of patent protection for Sorrento's platform technologies, and the risk that the development or commercialization of product candidates may infringe the intellectual property rights of others; the potential that Sorrento may require substantial additional funding in order to obtain regulatory approval for and commercialize Sorrento's proprietary G-MAB® fully-human antibody library platform technologies or product candidates; and additional risks set forth in Sorrento's filings with the Securities and Exchange Commission. These forward-looking statements represent Sorrento's judgment as of the date of this release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Sorrento undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made

Pharma&Biotech

Press Release



6042 Cornerstone Court West
Suite B
San Diego, CA 92121, USA

Lonza

Lonza Group Ltd
Muenchensteinerstrasse 38
4002 Basel, Switzerland

under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Further Information

Lonza Group Ltd
Head of Corporate Communications
Dominik Werner
Tel +41 61 316 8798
Fax +41 61 316 9798
dominik.werner@lonza.com

Lonza Group Ltd
Investor Relations
Dirk Oehlers
Tel +41 61 316 8540
Fax +41 61 316 9540
dirk.oehlers@lonza.com

Lonza Group Ltd
Media Relations
Melanie Disa
Tel +1 201 316 9413
Fax +1 201 696 3533
melanie.disa@lonza.com

Sorrento Therapeutics, Inc.
Chief Business Officer
Jaisim Shah
Tel + 1 (650) 996-2367
jshah@sorrentotherapeutics.com